DOW JONES, A NEWS CORP COMPANY
News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services.
DOW JONES
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Newsmart
  • NewsPlus
  • Private Markets
  • Risk & Compliance
  • WSJ.com
  • WSJ Pro
  • WSJ Conference
  • WSJ Video
NEWS CORP
  • Big Decisions
  • Business Spectator
  • Checkout51
  • Harper Collins
  • New York Post
  • PropTiger
  • REA
  • realtor.com
  • Storyful
  • The Australian
  • The Sun
  • The Times
ダウ平均 ▲
18867.93 -0.19%
  S&P 500 ▲
2181.90 -0.24%
  ナスダック ▲
5321.51 -0.23%
  米10年債 ▲
0/32 yield 2.357%
  原油 ▲
45.58 0.35%
  ユーロ/ドル ▲
1.0591 -0.34%
 
Subscribe Now Sign In
The Wall Street Journal
日本 (Japan)
  • U.S.
  • Asia
  • Europe
  • India
  • América Latina
  • Brasil
  • 中国 (China)
  • 日本 (Japan)
2016年11月20日
Sections
My Journal
  • ホーム
  • 経済
  • マーケット
  • ビジネス
  • テクノロジー
  • 国際
  • 国内
  • オピニオン・社説
  • ライフ
  • バロンズ
  • SHOW ALL SECTIONS HIDE ALL SECTIONS
    • 経済
      • 金融政策ウォッチ
      • Heard on the Street
    • マーケット
      • マーケットデータ
    • テクノロジー
      • ガジェットレビュー
    • 国際
      • 北米
      • 米大統領選特集
      • アジア・オセアニア
      • 欧州
      • 中東・アフリカ
      • China's World
      • China Real Time Report
    • 国内
      • 編集長インタビュー
    • オピニオン・社説
      • オピニオ ン
      • 社説
    • ライフ
      • キャリア
      • ヘルス
    HIDE ALL SECTIONS
Sign In
  • ホーム
  • 経済
    • 金融政策ウォッチ
    • Heard on the Street
  • マーケット
    • マーケットデータ
  • ビジネス
  • テクノロジー
    • ガジェットレビュー
  • 国際
    • 北米
    • 米大統領選特集
    • アジア・オセアニア
    • 欧州
    • 中東・アフリカ
    • China's World
    • China Real Time Report
  • 国内
    • 編集長インタビュー
  • オピニオン・社説
    • オピニオ ン
    • 社説
  • ライフ
    • キャリア
    • ヘルス
  • バロンズ
Search
Subscribe Sign In

Johnson & Johnson JNJ (U.S.: NYSE)

View All companies
  • AT CLOSE 4:01 PM EST 11/18/16
  • $115.36 USD
  • -0.41 -0.35%
  • Volume 7,605,710
  • AFTER HOURS 6:35 PM EST 11/18/16
  • $115.57 0.21 0.18%
  • AFTER HOURS Vol 112,063
  • Volume 7,605,710
  • 65 Day Avg Vol 6,734,961
  • 1 Day Range 114.81 - 115.92
  • 52 Week Range 94.28 - 126.07 (01/21/16 - 07/20/16)
  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • YTD
  • 1 Y
  • 3 Y
  • $
  • %
Advanced Charting Compare
  • Compare to Benchmark:
  • DJIA
  • S&P 500
  • GLOBAL DOW
  • NASDAQ
  • Health Care/Life Sciences
  • Compare to
  • Open 115.79
  • Prior Close 115.77 (11/17/16)
  • 1 Day
  • JNJ -0.35%
  • DJIA -0.19%
  • S&P 500 -0.24%
  • Health Care/Life Sciences -1.03%
  • Overview

News Johnson & JohnsonJNJ

    • 11/16/16
    • Press Release
    Johnson & Johnson Establishes Susan L. Lindquist Chair for Women in Science
    • Press Release
    • 11/14/16
    • The Wall Street Journal
    Study Suggests Heart Patients May Need Fewer Blood Thinners
    • The Wall Street Journal
    • 11/14/16
    • Dow Jones Newswires
    Study Suggests Heart-Disease Patients May Need Fewer Blood Thinners
    • Dow Jones Newswires
    • 11/14/16
    • MarketWatch.com
    5 big hurdles to repealing Obamacare
    • MarketWatch.com
    • 11/06/16
    • MarketWatch.com
    Drug companies spend $109 million to block vote to lower drug prices
    • MarketWatch.com
    • 11/05/16
    • Barron's
    Samsung BioLogics IPO: Too Expensive
    • Barron's
    • 11/01/16
    • Press Release
    Johnson & Johnson Announces Launch of Africa Innovation Challenge to Support Continent's Entrepreneurs and Develop Local Consumer Health Solutions
    • Press Release
    • 10/28/16
    • Press Release
    Johnson & Johnson Mourns the Loss of Susan Lindquist, Biomedical Research Pioneer and Member of the Johnson & Johnson Board of Directors
    • Press Release
    • 10/26/16
    • MarketWatch.com
    Senior-citizen portfolios are nearly doubling the returns of millennials this year
    • MarketWatch.com
    • 10/26/16
    • Press Release
    Johnson & Johnson to Participate in the 25th Annual Credit Suisse Health Care Conference
    • Press Release
    • 10/26/16
    • Press Release
    Research Reports on Drug Makers Equities -- Pfizer, Merck, AbbVie, and Johnson & Johnson
    • Press Release
    • 10/22/16
    • Barron's
    J&J Outperforms on Defense
    • Barron's
    • 10/20/16
    • Press Release
    Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2016
    • Press Release
    • 10/20/16
    • Press Release
    ( JNJ ) Post Earnings Coverage as Johnson and Johnson Profit Soars 27 Percent
    • Press Release
    • 10/20/16
    • Dow Jones Newswires
    E.ON to Invest $500M in Illinois Wind Farm
    • Dow Jones Newswires
    • 10/19/16
    • Press Release
    Johnson & Johnson Opens New Global Services Center In Tampa, Florida
    • Press Release
    • 10/19/16
    • Press Release
    Ortho Clinical Diagnostics to Present Data on Automation in Immunohematology, Three Products at 2016 AABB Annual Meeting
    • Press Release
    • 10/18/16
    • Dow Jones Newswires
    J&J Brushes off Looming Biosimilar Competition -- 2nd Update
    • Dow Jones Newswires
    • 10/18/16
    • The Wall Street Journal
    J&J Brushes Off Looming Biosimilar Competition
    • The Wall Street Journal
    • 10/18/16
    • Press Release
    3D Systems trade offers a 12% return in 213 days, or find similar option trades on Hawaiian Holdings, Johnson & Johnson, Melco Crown Entertainment, and Ambarella
    • Press Release
    • 10/18/16
    • Dow Jones Newswires
    U.S. Hot Stocks: Hot Stocks to Watch
    • Dow Jones Newswires
    • 10/18/16
    • Dow Jones Newswires
    J&J Again Buoyed by Pharmaceuticals -- Update
    • Dow Jones Newswires
    • 10/18/16
    • Dow Jones Newswires
    Johnson & Johnson Again Buoyed by Pharmaceuticals
    • Dow Jones Newswires
    • 10/18/16
    • Press Release
    Johnson & Johnson Reports 2016 Third-Quarter Results:
    • Press Release
    • 10/17/16
    • Dow Jones Newswires
    Pfizer Plans to Launch Remicade Biosimilar in November -- Update
    • Dow Jones Newswires
    • 10/17/16
    • The Wall Street Journal
    Pfizer Plans to Launch Remicade Biosimilar in November
    • The Wall Street Journal
    • 10/17/16
    • Dow Jones Newswires
    JPMorgan Sees $1B In Lost J&J Sales On Pfizer Biosimilar -- Market Talk
    • Dow Jones Newswires
    • 10/17/16
    • Dow Jones Newswires
    Pfizer Plans to Launch Remicade Biosimilar in November
    • Dow Jones Newswires
    • 10/17/16
    • WSJ Blogs
    U.S. Stocks Slip Amid Global Government Bond Selloff
    • WSJ Blogs
    • 10/17/16
    • MarketWatch.com
    What to expect from Johnson & Johnson earnings
    • MarketWatch.com
    • 10/15/16
    • Dow Jones Newswires
    This Week: Preview
    • Dow Jones Newswires
    • 09/21/16
    • Press Release
    Drug Makers Stocks Under Review -- Pfizer, Merck, AbbVie, and Johnson & Johnson
    • Press Release
    • 09/20/16
    • Press Release
    Johnson & Johnson Advances Commitment to Improve Global Health and Well-Being
    • Press Release
    • 09/20/16
    • Press Release
    Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
    • Press Release
    • 09/19/16
    • Press Release
    ( JNJ ) Blog Coverage Johnson & Johnson Acquires Abbott Laboratories Optic Unit
    • Press Release
    • 09/17/16
    • Press Release
    Johnson & Johnson Partners with Global Citizen to Improve the Trajectory of Human Health Around the World
    • Press Release
    • 09/17/16
    • Press Release
    Johnson & Johnson to Participate in 2016 Morgan Stanley Global Health Care Conference
    • Press Release
    • 09/16/16
    • Press Release
    Johnson & Johnson Announces Agreement to Acquire Abbott Medical Optics
    • Press Release
    • 09/12/16
    • Press Release
    Johnson & Johnson Announces World Health Organization will Review Ebola Vaccine Regimen for Emergency Use Assessment and Listing (EUAL)
    • Press Release
    • 09/07/16
    • Press Release
    Johnson & Johnson Partners with Global Citizen to Improve the Trajectory of Human Health Around the World
    • Press Release
load more
Key Stock Data
?
P/E Ratio (TTM)
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing 12 month period.
Earnings Per Share (TTM)
A company's net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding.
Market Capitalization
Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple common share classes, market capitalization includes both classes.
Shares Outstanding
Number of shares that are currently held by investors, including restricted shares owned by the company's officers and insiders as well as those held by the public.
Public Float
The number of shares in the hands of public investors and available to trade. To calculate, start with total shares outstanding and subtract the number of restricted shares. Restricted stock typically is that issued to company insiders with limits on when it may be traded.
Dividend Yield
A company's dividend expressed as a percentage of its current stock price.

Key Stock Data

  • P/E Ratio (TTM)
    20.42 (11/18/16)
  • EPS (TTM)
    $5.65
  • Market Cap
    $313.84 B
  • Shares Outstanding
    2.74 B
  • Public Float
    2.73 B
  • Yield
    2.77% (11/18/16)
  • Latest Dividend
    $0.80 (12/06/16)
  • Ex-Dividend Date
    11/18/16
?
Shares Sold Short
The total number of shares of a security that have been sold short and not yet repurchased.
Change from Last
Percentage change in short interest from the previous report to the most recent report. Exchanges report short interest twice a month.
Percent of Float
Total short positions relative to the number of shares available to trade.

Short Interest (10/31/16)

  • Shares Sold Short
    17.99 M
  • Change from Last
    -12.47%
  • Percent of Float
    0.66%
?
Money Flow Uptick/Downtick Ratio
Money flow measures the relative buying and selling pressure on a stock, based on the value of trades made on an "uptick" in price and the value of trades made on a "downtick" in price. The up/down ratio is calculated by dividing the value of uptick trades by the value of downtick trades. Net money flow is the value of uptick trades minus the value of downtick trades. Our calculations are based on comprehensive, delayed quotes.

Stock Money Flow

  • Uptick/Downtick Trade Ratio
    0 2
    0.38
    Net Money Flow ($)
    -179.67 M

    Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.

Advertisement

Competitors JNJ

Company Change P/E (TTM)
GSK

GlaxoSmithKline PLC ADR

-0.88% -0.34 313.15
NVS

Novartis AG ADR

-2.62% -1.90 25.09
ABT

Abbott Laboratories

-1.36% -0.55 44.00
LLY

Eli Lilly & Co.

-1.34% -1.04 33.59
PFE

Pfizer Inc.

-0.79% -0.25 31.32
SYK

Stryker Corp.

+0.71% +0.79 25.38
RHHVF

Roche Holding AG Part. Cert.

-0.26% -0.60 21.47
SNY

Sanofi ADR

-2.34% -0.96 22.48
MRK

Merck & Co. Inc.

-1.32% -0.83 31.57
MDT

Medtronic PLC

-1.06% -0.87 31.49
  • More information on JNJ
  • Competitor Data Provided By: capital cube

Profile JNJ

Johnson & Johnson operates as an investment holding company with interests in health care products. It engages in research and development, manufacture and sale of personal care hygienic products, pharmaceuticals and surgical equipment. The company, through its subsidiaries...

One Johnson & Johnson Plaza
New Brunswick New Jersey 08933
United States

  • Email
  • Website
  • Map
  • Employees 127,100
    Sector Pharmaceuticals
  • Sales or Revenue 70.20 B
    Industry Health Care/Life Sciences
  • 1Y Sales Change -5.56%
    Fiscal Year Ends December 31 Download Reports
  • Alex Gorsky Chairman & Chief Executive Officer
  • Dominic J. Caruso Chief Financial Officer & Vice President
  • Paulus Stoffels Chief Scientific Officer
  • Sandra E. Peterson Chairman-Worldwide Group
  • More

Research & Ratings Johnson & JohnsonJNJ

Per-Share Earnings, Actuals and Estimates

  • Quarterly
  • Annual
JNJ will report FY 2016 earnings on 01/24/2017 JNJ will report Q4 earnings on 01/24/2017
Actual Analyst Range Consensus
2.00 1.80 1.60
Actual 1.44
1.42
Actual 1.68
1.65
Actual 1.74
1.68
Actual 1.68
1.65
1.57
1.76
Q42015 Q12016 Q2 Q3 Q4 Q12017
10.00 7.50 5.00 2.50 0.00
Actual 5.48
6.18
6.71
7.14
7.57
FY 2015 FY 2016 FY 2017 FY 2018
Q4 2016 Estimate Trends
Current: $1.57
1 month ago: $1.57
3 months ago: $1.58
Q1 2017 Estimate Trends
Current: $1.76
1 month ago: $1.77
3 months ago: $1.76
FY 2016 Estimate Trends
Current: $6.71
1 month ago: $6.69
3 months ago: $6.69
FY 2017 Estimate Trends
Current: $7.14
1 month ago: $7.10
3 months ago: $7.10
  • More

Financials Johnson & JohnsonJNJ

  • Quarterly
  • Annual

Net Income

0 2B 4B 6B
Sep 2015 Dec 2015 Mar 2016 Jun 2016 Sep 2016
0 5B 10B 15B 20B
'11 '12 '13 '14 '15
Sep 2016 5-quarter trend
Net Income Growth +27.22%
Sales or Revenue 17.82 B
Sales or Revenue Growth +4.05%
EBITDA -
2015 5-year trend
Net Income Growth -5.60%
Sales or Revenue 70.20 B
Sales or Revenue Growth -5.56%
EBITDA +22.11 B
  • More
  • Overview

Notes & Data Providers

Real-time U.S. stock quotes reflect trades reported through Nasdaq only.

International stock quotes are delayed as per exchange requirements. Indexes may be real-time or delayed; refer to time stamps on index quote pages for information on delay times.

Quote data, except U.S. stocks, provided by SIX Financial Information.

Data is provided "as is" for informational purposes only and is not intended for trading purposes. SIX Financial Information (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Data may be intentionally delayed pursuant to supplier requirements.

All of the mutual fund and ETF information contained in this display was supplied by Lipper, A Thomson Reuters Company, subject to the following: Copyright © Thomson Reuters. All rights reserved. Any copying, republication or redistribution of Lipper content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Lipper. Lipper shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Bond quotes are updated in real-time. Source: Tullett Prebon.

Currency quotes are updated in real-time. Source: Tullet Prebon.

Fundamental company data and analyst estimates provided by FactSet. Copyright FactSet Research Systems Inc. All rights reserved.

Advertisement
  • Wall Street Journal
  • 日本 (Japan)
    • U.S.
    • Asia
    • Europe
    • India
    • América Latina
    • Brasil
    • 中国 (China)
    • 日本 (Japan)
  • Subscribe NowSign In

  • Newsletter
  • WSJ Membership Benefits
  • Download WSJ Apps
  • Customer Center
  • Legal Policies
  • Subscribe
  • Sign In
  • TOP«
  • Customer Service

  • Customer Center
  • Contact Us
  • About Houjin Subscribing
  • 学生割引購読
  • About Us
  • Ads

  • About Ads
  • Tools & Features

  • iPhone App
  • iPad App
  • Android App
  • Newsletter
  • About Japanese Blog Parts
  • More

  • Events
  • Jobs at WSJ
    • Facebook
    • Twitter
    • Line
    • Google+
    • YouTube
    • Podcasts
    • Snapchat
    • GooglePlay
    • AppStore
    • Windows10
  • Dow Jones Products
  • Barron's
  • BigCharts
  • DJX
  • Dow Jones Newswires
  • Factiva
  • Financial News
  • Mansion Global
  • MarketWatch
  • Private Markets
  • realtor.com
  • Risk & Compliance
  • WSJ Conference
  • WSJ Pro Central Banking
  • WSJ Video
  • WSJ Wine
  • BallBall
  • Privacy Policy
  • Cookie Policy
  • Tokusyo
  • Data Policy
  • Subscriber Agreement & Terms of Use
  • Copyright ©2016 Dow Jones & Company, Inc. All Rights Reserved.